The existence of FGFR1-5-HT1A receptor heterocomplexes in midbrain 5-HT neurons of the rat: relevance for neuroplasticity by Borroto-Escuela, Dasiel O. et al.
Cellular/Molecular
The Existence of FGFR1–5-HT1A Receptor Heterocomplexes
in Midbrain 5-HT Neurons of the Rat: Relevance
for Neuroplasticity
Dasiel O. Borroto-Escuela,1Wilber Romero-Fernandez,1Mileidys Pe´rez-Alea,2Manuel Narvaez,3
Alexander O. Tarakanov,4 Giuseppa Mudo´,5 Luigi F. Agnati,6 Francisco Ciruela,7Natale Belluardo,5 and Kjell Fuxe1
1Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden, 2School of Life and Health, Aston University, Birmingham B4 7ET,
United Kingdom, 3Department of Physiology, School of Medicine, University of Ma´laga, 29071 Ma´laga, Spain, 4St. Petersburg Institute for Informatics and
Automation, Russian Academy of Sciences, 199178 Saint Petersburg, Russia, 5Department of Experimental Biomedicine and Clinical Neurosciences,
Laboratory of Molecular Neurobiology, University of Palermo, IT-90134 Palermo, Italy, 6Istituto Di Ricovero e Cura a Carattere Scientifico, 30 126 Lido
Venice, Italy, and 7Unitat de Farmacologia, Departament Patologia i Terape`utica Experimental, Universitat de Barcelona, 08907 Barcelona, Spain
The ascending midbrain 5-HT neurons to the forebrain may be dysregulated in depression and have a reduced trophic support. With in
situ proximity ligation assay (PLA) and supported by coimmunoprecipitation and colocation of the FGFR1 and 5-HT1A immunoreactiv-
ities in themidbrain raphe cells, evidence for the existence of FGFR1–5-HT1A receptor heterocomplexes in the dorsal andmedian raphe
nuclei of the SpragueDawley rat aswell as in the ratmedullary rapheRN33B cells has beenobtained. Especially after combinedFGF-2 and
8-OH-DPAT treatment, amarked and significant increase in PLA clusterswas found in theRN33B cells. Similar resultswere reachedwith
the FRET technique in HEK293T cells, where TM-V of the 5HT1A receptor was found to be part of the receptor interface. The combined
treatment with FGF-2 and the 5-HT1A agonist also synergistically increased FGFR1 and ERK1/2 phosphorylation in the raphe midline
area of themidbrain and theRN33B cells aswell as their differentiation, as seen fromdevelopment of the increased number and length of
extensions per cell and their increased 5-HT immunoreactivity. These signaling and differentiation events were dependent on the
receptor interface since they were blocked by incubation with TM-V but not by TM-II. Together, the results indicate that the 5-HT1A
autoreceptors by being part of a FGFR1–5-HT1A receptor heterocomplex in themidbrain raphe 5-HTnerve cells appear to have a trophic
role in the central 5-HT neuron systems in addition to playing a key role in reducing the firing of these neurons.
Introduction
Compelling evidence shows that the alleviationof depression caused
by serotonin-selective reuptake inhibitors (SSRIs) is produced by
increasing the availability of serotonin at the postjunctional 5-HT
receptor subtypes in combination with a downregulation of the
5-HT1A autoreceptors in the raphe regions (Albert et al., 1996;
Artigas et al., 1996). A dysregulation of the 5-HT1A autoreceptors
leading to a marked reduction of the firing rate in the ascending
raphe-forebrain5-HTneuronshasbeen implicated inmajordepres-
sion (Albert et al., 2011). It seems possible that a certain balance of
activity at different postjunctional 5-HT receptor subtypes of the
seven 5-HT receptor families identified (Hoyer et al., 2002) needs to
be developed with time through adaptive changes to counteract the
depression (Fuxe et al., 1991). In fact, certain antidepressant drugs
may as part of their action block certain 5-HT2-like receptors (Fuxe
et al., 1977; Ogren et al., 1979; Peroutka and Snyder, 1979, 1980).
Antidepressant drugs and chronic electroconvulsive shock
treatment increase the expression of FGF-2 in frontal cortices and
hippocampus (Follesa et al., 1994;Gwinn et al., 2002;Mallei et al.,
2002; Maragnoli et al., 2004), suggesting a beneficial role of
FGF-2 inmood disorders. It is therefore of interest that FGFR1 is
constitutively expressed in neurons of target brain regions in-
volved in depression, including the raphe 5-HTnuclei (Belluardo
et al., 1997). FGF-2, a trophic factor binding to FGFR1, is widely
expressed in the brain both in astrocytes and neurons (Fuxe et al.,
1996) and is coexpressed in the perikarya of practically all raphe
5-HT nerve cells (Chadi et al., 1993; Fuxe et al., 1996).
The above findings open up the possibility that antidepressant
drugs, by increasing extracellular 5-HT levels, leading to an en-
hancement of the 5-HT1A autoreceptor signaling in the raphe
nuclei, can cause an activation of the FGF-2/FGFR1 mechanism
in the raphe 5-HT nerve cells. In line with this hypothesis, ex-
tended treatment with the SSRI zimelidine causes increases in
5-HT immunofluorescence in the dorsal raphe (Fuxe et al.,
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1983). The receptors for epidermal growth factor, platelet-
derived growth factor, insulin-like growth factor-1, FGFs, and
neurotrophins can, in fact, be transactivated in response toGPCR
activation even in the absence of neurotrophic factor binding at
the cell surface via direct (heteromeric receptor complexes)
and/or indirect GPCR/RTK receptor interactions (Luttrell et al.,
1999; Lee and Chao, 2001; Kotecha et al., 2002; Lee et al., 2002;
Ferguson, 2003; Rajagopal et al., 2004; Shah and Catt, 2004;
Berghuis et al., 2005; Fuxe et al., 2007). Evidence is here presented
for the existence of FGFR1–5-HT1A receptor heterocomplexes in
the mesencephalic raphe 5-HT nerve cells. Upon coactivation
of the receptor protomers they produce a substantial enhance-
ment of plasticity in stable cell lines of medullary raphe 5-HT
nerve cells. We therefore propose a new role of the 5-HT autore-
ceptors in the central 5-HT nerve cell bodies, namely one of
neurotrophism through transactivation of FGFR1 in the discov-
ered receptor heterocomplex as observed both in in vivo and in
vitro experiments.
Materials andMethods
Chemicals, reagents, and drug administration. (S)-N-tert-Butyl-3-(4-(2-
methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide dihydrochloride
((S)-WAY 100135 dihydrochloride), 2-[(1,2-dihydro-2-oxo-3H-indol
3-ylidene)methyl]-4-methyl-1H-pyrrole-3-propanoic acid (SU 5402),
N-[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido
[2,3-d]pyrimidin-7-yl]-N-(1,1-dimethylethyl)urea (PD173074), and ()-
7-hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT
hydrobromide) were purchased from Tocris Bioscience. FGF-2 was pur-
chased from Cell Signaling Technology. DMEM, penicillin/streptomycin,
and fetal bovine serum were purchased from Invitrogen. Restriction en-
zymeswere fromNewEnglandBiolabs, andcoelenterazine400wasobtained
fromMRW.The injectedamounts (intracerebroventricularly)were60gof
8-OH-DPAT and 50 ng of FGF-2 unless otherwise indicated. Phospho-FGF
Receptor 1 (Tyr653/654) (55H2) mouse monoclonal antibody was pur-
chased fromCell SignalingTechnology.Rabbit polyclonal antiserumagainst
5-HT1A receptor (ab44635), mouse monoclonal [M2F12] FGFR1 (ab829)
antibodies were obtained from Abcam. Rabbit monoclonal anti-5-HT1A
(vtg544) antibodywas obtained fromVTGBiosciences.Monoclonalmouse
anti-phospho-ERK1/2 and rabbit monoclonal anti-5-HT antibodies were
from Sigma-Aldrich. Mouse anti-NeuN monoclonal antibody was pur-
chased fromMillipore. Secondary infraredprobe-labeled rabbit-anti-mouse
antibodieswere fromLI-CORBiosciences. Alexa Fluor 488-conjugated goat
anti-mouse IgG and the Alexa Fluor 546-conjugated goat anti-rabbit IgG
were from Invitrogen.
Plasmid constructs. The cDNA encoding the human 5-HT1A and FGFR1
without its stop codon was subcloned in pGFP 2-N1 (PerkinElmer)
and pEYFP-N1 (Clontech) using standard molecular biology and
PCR techniques.
Cell culture, transfection, and RNA interference. HEK293T or RN33B
cells (a CNS-derived neuronal precursor cell line; Lundberg et al., 2002;
American Type Culture Collection) were grown in DMEM/F12 supple-
mented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, and
10% (v/v) fetal bovine serum at 37°C and in an atmosphere of 5% CO2.
For transfection, cells were plated in 6-well dishes at a concentration of
1  106 cells/well or in 75 cm2 flasks and cultured overnight before
transfection. Cells were transiently transfected (cDNA molar ratio 1:1)
using linear PolyEthylenImine reagent (PEI) (Polysciences Inc.). siRNAs
against rat FGFR1 and 5-HT1A (Dharmacon) were from Thermo Scien-
tific. Nonsilencing siRNA Alexa Fluor 488 was from Qiagen (catalog
#1022563) andused as a negative control. Cells were plated the day before
transfection in 12-well culture dishes coated with poly-D-lysine (BD Bio-
Coat) and then transfected with the corresponding SMARTpool siRNA
kit (Dharmacon, Thermo Scientific).
Transmembrane peptide treatment. A series of peptides, representing
each of the predicted TM segments for the human 5-HT1A (UniProt
identifier number P08908), were synthesized by VTG Biosciences by
using 9-fluorenylmethoxycarbonyl chemistry and purified by means of
HPLC analysis (reverse phaseC4 column) to98%purity. TM-I peptide
consisted of residues 37–62 (VITSLLLGTLIFCAVLGNACVVAAIA);
TM-II peptide of residues 74–98 (LIGSLAVTDLMVSVLVLPMAALYQ
V); TM-III peptide of residues 110–132 (DLFIALDVLCCTSSILHLCAIA
L); TM-IV peptide of residues 153–178 (AAALISLTWLIGFLISIPPMLG
WRTP); TM-V peptide of residues 192–217 (DHGYTIYSTFGAFYIPLLL
MLVLYGR); TM-VI peptide of residues 346–367 (TLGIIMGTFILCWL
PFFIVALV); and TM-VII peptide of residues 379–403 (TLLGAIINWL
GYSNSLLNPVIYAYF). At the C-terminal juxtamembrane sequence of
each TMpeptide was introduced the tribasic sequence (RKR) as found in
many membrane proteins to reduce possible artifact formation through
disulfide bridges and to ensure incorporation into the plasmamembrane
of cells, as has been demonstrated previously (Bennasroune et al., 2004,
2005). Immediately before use, the peptides were solubilized in dimethyl
sulfoxide (DMSO) and diluted in the corresponding cell culturemedium
to yield a final concentration of 1% DMSO. We verified that, for each
tested concentration of DMSO alone, no effect on cell viability was ob-
served. Cells were incubated with the above mentioned peptides at 37°C
for 2 h before performing FRET analysis or signaling assays. Incorpora-
tion of the peptide into cellular membranes under these conditions was
checked with a rhodamine-labeled TM-I peptide.
Double immunolabeling histochemistry. Adult aged-matched male
mice were anesthetized and perfused intracardially with 4% (w/v) para-
formaldehyde/PBS. Brains were removed, postfixed by immersion over-
night in 4% paraformaldehyde/PBS, and coronal sections (20 m) were
cut on a vibratome and processed for free-floating immunohistochem-
istry. Sections were permeabilized with buffer A containing 0.2% Triton
X-100 for 5 min, and then preincubated in a blocking buffer containing
0.3% (w/v) Triton and 4% (w/v) bovine serum albumin. After 1 h at
room temperature, sections were labeled with the indicated primary an-
tibodies for 1 h, extensively washed, and stained with the indicated
fluorescence-labeled secondary antibodies. Samples were rinsed and vi-
sualized on a Leica SP2 confocal microscope. The primary antibodies
used were as follows: rabbit polyclonal antiserum against 5-HT1A recep-
tor (ab44635) (5 g/ml; Abcam) and mouse monoclonal [M2F12]
(ab829) antibodies against FGFR1 (5 g/ml;Abcam). The secondary an-
tibodies used were as follows: Alexa Fluor 488-conjugated goat anti-
mouse IgG (1:2000; Invitrogen), and Alexa Fluor 546-conjugated goat
anti-rabbit IgG (1:2000; Invitrogen).
Proximity ligation in situ assay (Duolink). In situ proximity ligation
assay (PLA) was performed as described previously (So¨derberg et al.,
2006; Borroto-Escuela et al., 2010, 2011; Trifilieff et al., 2011). Free-
floating sections and RN33B cell cultures were used with the following
primary antibodies: rabbit monoclonal anti-5HT1A (VTG Biosciences)
andmousemonoclonal anti-FGFR1 (Abcam). Control experiments used
only one primary antibody or cells transfected with cDNAs encoding
only one type of receptor. PLA signal was visualized and quantified by
using a confocal microscope Leica TCS-SL confocal microscope (Leica)
and the Duolink Image Tool software.
Coimmunoprecipitation experiments. For immunoprecipitation,
HEK293T cell membranes from transiently transfected cells or raphe
membranes obtained from the caudal midline area of the midbrain teg-
mentum, containing the dorsal raphe and medianus raphe, were solubi-
lized in ice-cold RIPA buffer (comprising, in mM: 50 Tris-HCl, pH 7.4,
100 NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.2% SDS, and
1 EDTA) for 30 min on ice. The solubilized preparation was then centri-
fuged at 10,000 g for 30min. The supernatant (1mg/ml)was processed
for immunoprecipitation, each step of which was conducted with con-
stant rotation at 04°C. The supernatant was incubated overnight with
the indicated antibody. Then 50 l of a suspension of TrueBlot anti-
mouse Ig IP beads (eBioscience) was added and the mixture was
incubated overnight. Subsequently, the beads were washed twice with
ice-cold RIPA buffer, twice with ice-cold RIPA buffer diluted 1:10 in TBS
(50mMTris-HCl, pH 7.4, 100mMNaCl), and once with TBS, and aspirated
todrynesswith a 28-gaugeneedle. Then, 100l of SDS-PAGE sample buffer
(0.125 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.004% bromphenol
blue) was added to each sample. Immune complexes were dissociated by
adding fresh DTT (50 mM final concentration) and heating to 100°C for 10
min. Proteins were resolved by SDS/PAGE performed in 10% polyacryl-
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amide gels. Proteins were transferred to PVDFmembranes using a semidry
transfer system and immunoblotted with the indicated antibody and then
with HRP-conjugated goat anti-rabbit IgG or HRP-conjugated anti-mouse
IgG TrueBlot ULTRA (eBioscience). The immunoreactive bands were de-
veloped using a chemiluminescent detection kit (Pierce).We are aware that
we have not used midbrain sections from 5-HT1A-null mutant mice as
negative controls. However, this additional control will be made in further
experiments, although the 5-HT1A-FGFR1 coimmunoprecipitation data in
the midbrain could be validated in cellular models.
FRET experiments. Forty-eight hours after transfection, HEK293T
cells with constant (1g) or increasing amounts of cDNA of FGFR1GFP2
and 5-HT1AYFP or 5-HT2AYFP, respectively, were rapidly washed twice
in PBS, detached, and resuspended in the same buffer. Cell suspensions
(40 g of total protein) were distributed in duplicates into 96-well mi-
croplates, and GFP2 and YFP fluorescence were measured with a
POLARstar Optima plate reader (BMG Labtech), using excitation filters
at 410 nm (10 nmbandwidth) and 485 nm (12 nmbandwidth), as well as
emission filters corresponding to 510 nm (10 nm bandwidth), and 530
nm (10 nm bandwidth), respectively. Mock-transfected cells were used
for background subtraction. FRET signals were collected using 410/10
nm excitation and 530/10 nm emission filters. Removal of acceptor bleed-
through and correction of acceptor fluorescence intensity changeswere per-
formed as previously described (Borroto-Escuela et al., 2010, 2011).
In cell Western phosphorylation assay. Nondifferentiated and in some
cases differentiated RN33B cells were treated at the indicated concentra-
tion and times of each 5-HT1A and FGFR1 agonist or antagonist and
then fixed in a final concentration of 4% paraformaldehyde. After fixing,
the cells were permeabilized by washing 5 times (0.1% Triton X-100 in
PBS), blocked for 90 min at room temperature in LI-COR Odyssey
Blocking Buffer, and then incubated overnight at 4°C with primary
monoclonal mouse anti-phospho-ERK1/2 antibody (Sigma-Aldrich, di-
luted 1:10,000) or primarymonoclonalmouse anti-phospho-FGFR1 an-
tibody (Cell Signaling Technology, diluted 1:1000). Then, after extensive
wash, cells were incubated in the dark with secondary infrared probe-
labeled rabbit-anti-mouse antibodies (diluted 1:1500) and normaliza-
tion stains (DRAQ5, Sapphire700) for 1 h at room temperature, washed,
and scanned by the Odyssey infrared scanner (LI-COR Biosciences).
RN33B cell differentiation. Sterile poly-D-lysine-coated coverslips were
used to grow RN33B cells at a density of 2  105 cells per 10 cm2.
Agonists were added to nondifferentiated cells during 48 h after which
the medium was changed and the same ligands were added to fresh
nonsupplemented medium and incubation was continued for 48 h at
37°C. Cells were then fixed with 4% cold paraformaldehyde (w/v), the
coverslips were mounted on slides, and the cells were analyzed. Bright-
field images were obtained using an Olympus IX70 with a Q-Fire CCD
camera. Average number of extensions per 1000 cells was determined
and the mean extension lengths from measurement of 100 cells were
quantified per condition in three independent experiments; length was
converted into micrometers and analyzed for statistical significance.
Studies on RN33B cell differentiated before agonist treatment. At a conflu-
ence of 80%, cells were transferred to complete serum-free B16 medium
(0.5%BSA, SigmaAldrich) andwere differentiated by shifting the tempera-
ture from 33°C (2 d incubation) to 39°C (2 d) and 5%CO2 in room air.
5-HT immunocytochemistry. RN33B cells were treated under different
pharmacological conditions as indicated and grown for an additional
48–56 h (in the case of TM peptide incubation, neurons were incubated
2 h before pharmacological treatment). RN33B cells were stained with
rabbit anti-5-HT monoclonal antibody (5 g/ml; Sigma-Aldrich) and
mouse anti-NeuN monoclonal antibody (5 g/ml; Millipore). The sec-
ondary antibodies used were as follows: Alexa Fluor 488-conjugated goat
anti-mouse IgG (1:2000; Invitrogen), Alexa Fluor 546-conjugated goat
anti-rabbit IgG (1:2000; Invitrogen). Each image was acquired with a
Leica SP2 confocal microscope (40) and consisted of one image as a
single z-scan image. Acquisition of microscopy images and 5-HT immu-
noreactivity semiquantifications was performed by investigators blind to
the experimental condition. 5-HT immunoreactivity semiquantification
is expressed as 5-HT immunoreactivity field area/number of NeuN-
positive cells. Typically, images of 200–300 cells per condition were cap-
tured for each experiment and four independent experiments were
performed. The application settings were adjusted at the beginning of
analysis and kept the same for all images in the experiment.
Animals and drugs. Male Sprague Dawley rats, 8 weeks old, weighing
310–350 g and obtained from Charles River Laboratories, were used for
all experiments. The animals were housed under a 12 h light/dark cycle
under constant environmental conditions, with ambient temperature of
21 2°C, relative humidity of 40–50%, and with food and water avail-
able ad libitum. The number of rats in each treated group was three and
the total number of rats used in this studywas 36. All efforts weremade to
minimize the number of animals used and their suffering. All experimen-
tal procedures were performed in accordance with the European Com-
munities Council Directive (86/609/EEC).
Surgical preparation. Rats were anesthetized with sodium pentobarbi-
tal (40 mg/kg, i.p., Nembutal injection, Dainippon Pharmaceutical) and
placed in a stereotaxic frame. Body temperature was maintained at 37°C
and a cannula for intracerebroventricular injection of samples was im-
planted into the right lateral ventricle according to coordinates obtained
from the work of Paxinos and Watson (1986) [anterior–posterior (AP)
coordinates referred to bregma, lateral (L) coordinates to the midsagittal
suture line, and ventral (V) coordinates to the surface of the skull; AP,
1.4 mm; L,2.2 mm; and V,4.3 mm (injection site)]. A permanent
guide cannula was maintained in place by dental cement anchored by
stainless screws fixed to the skull and fitted with an obturator. Five days
after surgery, the obturators were removed and a 28-gauge injector can-
nula was inserted extending 1.5 mm below the tip of the guides. The
microinjection cannula was connected via PE-20 tubing to a Hamilton
syringe mounted on a syringe pump (Harvard Apparatus). Rats were
microinjected with recombinant human FGF-2 (50 ng), 8-OH-DPAT
(0.2 M), combined treatment with TM-II synthetic peptide (0.4 M),
combined treatment with TM-V synthetic peptide (0.4 M), combined
treatment or artificial CSF (aCSF) for a control group. Fresh solutions
were prepared immediately before the injections by dissolving the pep-
tides/agonists in aCSF (composition of the aCSF solution, in mM: 120
NaCl, 20 NaH2CO3, 2 KCl, 0.5 KH2PO4, 1.2 CaCl2, 1.8 MgCl2, 0.5
Na2SO4, and 6.8 D-glucose). Total volumes were infused (FGF-2, 2 l;
8-OH-DPAT, 3l; TM synthetic peptides, 3l) in freelymoving animals
at 2.0 l/min, and injection cannula was left in place for another minute
to prevent backflow of the solution. The animals were killed 6, 12, or 24 h
after the infusions.
Data analysis. The number of samples (n) in each experimental con-
dition is indicated in figure legends. All data were analyzed using the
commercial program Prism 4.0 (GraphPad). When two experimental
conditions were compared, statistical analysis was performed using an
unpaired t test. Otherwise, statistical analysis was performed by one-way
ANOVA followed by Tukey’s Multiple Comparison post hoc test. The P
value 0.05 and lower was considered significant. FRET isotherms were
fitted using a nonlinear regression equation assuming a single binding
site.
Results
FGFR1–5-HT1A receptor heterocomplexes in the dorsal and
median raphe nuclei, in RN33B and HEK293T cells
We used three different approaches: in situ PLA, coimmunopre-
cipitation, and the FRET technology, supplemented with double
immunohistochemistry.
Midbrain raphe region
In situ PLA
PLA-positive red clusters were found in large number of nerve
cells of the dorsal and median raphe nuclei, but were absent else-
where in the surrounding areas e.g., in the deep gray layer of the
superior colliculus and the central periaqueductal gray, dorsome-
dial region (Fig. 1A). The specificity was demonstrated by the fact
that no PLA clusters were observed in HEK293T cells singly
transfected with FGFR1 or with the 5-HT1A receptors (Fig. 1B).
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Coimmunoprecipitation
Coimmunoprecipitation was performed on extracts of the caudal
midlinemidbrain area containing the dorsal andmedian raphe nu-
clei (see Notes). The bottom panel in the supplemental material
displays the immunoblot obtained with anti-5HT1A antibodies re-
vealing the presence and position of the 5-HT1A-immunoreactive
bands after immunoprecipitation of the FGFR1 receptors. Further-
more, coimmunoprecipitation experiments were performed in tran-
siently transfected HEK293T cells coexpressing FGFR1 and 3xHA-
5HT1A receptors (Fig. 1C), corroborating the results on brain.
Figure 1. FGFR1 and 5-HT1A receptor heterocomplexes and their agonist regulation. A, Detection of neuronal cytoplasmatic FGFR1–5-HT1A receptor heterocomplexes (seen as red clusters indicated by
arrows)indorsalandmedianraphenucleiby insituPLA;nucleiareshowninblue(DAPI).Scalebars:fourtoppanels,10m;fourbottompanels,50m.C,Cortex;cc,corpuscallosum;MnR,medianraphenucleus;
DR,dorsal raphenucleus; CGD, central graydorsal part;DpG,deepgray layerof the superior colliculus.B, Specific in situPLAcontrolswereperformed inHEK293T cells.HEK293T cellswere transiently transfected
withonlyFGFR1or5-HT1Aorcotransfected(cDNAmolarratio1:1)withbothreceptorsandgrownasdescribedinMaterialsandMethods.Afterfixation, insituPLAwasperformedwithFGFR1-and5-HT1A-specific
antibodies, followedbyPLA reagents. The detected receptor heterocomplexes are representedby the fluorescent PLApuncta (red clusters). Eachpunctum represents a high concentration of fluorescence from
the single-molecule amplification resulting from a several hundredfold replication of the DNA circle formed as a result of the probe proximity. Nuclei are shown in blue (DAPI). Scale bars, 10m. C, Specific
coimmunoprecipitation of FGFR1 and 5-HT1A in HEK293T cells. HEK293T cells were transfected with FGFR1 alone, 5-HT1A receptor alone, or combined FGFR1–5-HT1A cDNA. The solubilized lysates were
incubated with anti-HA (top) or anti-FGFR1 (bottom) to immunoprecipitate the 3xHA-5-HT1A or FGFR1 receptors, respectively, and the resultant immunoprecipitates were examined with Western blot for
anti-FGFR1 (top) or anti-HA (bottom) immunoreactivity. As shown in the right lanes of both panels, specific coimmunoprecipitation of FGFR1 and 3xHA-5HT1Awas observed. The positions ofmolecularmass
standardsare indicatedontherightsideofeachpanel.D,FGFR1(inred)and5-HT1A(ingreen) immunoreactivitiesareobservedinthesamesectionandshowntocolocalize indorsalandmedianraphenervecells
as seen fromtheyellow-orangecolor thatdeveloped(merger). Scalebars,10m.E, IncreasedFGFR1–5-HT1Areceptorheterocomplex formationuponreceptor coactivation in rat rapheRN33Bcells. Cellswere
treatedwithvehicle (), 8-OH-DPAT(100nM), FGF-2 (50ng/ml), or combined8-OH-DPATFGF-2 (100nMand50ng/ml, respectively)andeachTMpeptide (0.4M) for24h,andsampleswereprocessed for
detectionof in situPLAsignals. Scalebar,75m.e1,Quantificationof receptor complexesas redclusters/DAPI-positivenucleiwasmade in25cellsperplateandperformedonfourplates. Thuseachpoint in the
scatterplotrepresentonecellandall thecells (100cells) fromthefourdifferentexperimentsare included.Thelines ineachgrouprepresentthemeanvalue.Statisticalanalysiswasperformed(n4)byone-way
ANOVAfollowedbyTukey’sMultipleComparisonposthoc test. 8-OH-DPAT (100nM)andFGF-2 (50ng/ml)groupsare significantlydifferent comparedwithvehicle (**p0.01), combined8-OH-DPATFGF-2
group is significantlydifferent comparedwith8-OH-DPAT (100nM)andFGF-2 (50ng/ml)alonegroup (p0.001)or vehicle (***p0.001). 8-OH-DPATFGF-2TM-Vgroup is significantlydifferent
comparedwithcombined8-OH-DPATFGF-2and8-OH-DPATFGF-2TM-IIgroups(ŒŒŒp0.001).F,FRETshowsspecific5-HT1AandFGFR1heteromerizationinHEK293Tcells.FRETsaturationcurves
weregeneratedinHEK293TcellsexpressingafixedamountofFGFR1-GFP2andincreasingamountsof5-HT1A-YFPor5HT2A-YFP.Cellswerepreincubated10minwithvehicleorwith8-OH-DPATandFGF-2(100
nMand50ng/ml).TheFRETmaxvaluesweresignificantlyincreasedbycombined8-OH-DPATandFGF-2treatmentversusvehicle(**p0.01),andthecombinedtreatmentFRET50valuewassignificantlyreduced
versusvehicle(***p0.001).The5-HT1A/FGFR1curvefittedbettertoasaturationcurvethantoalinearregressionasfoundwith5HT2A/FGFR1(Ftest,p0.001).DataaremeansSEM(n5).f1,Theeffect
of different 5-HT1A receptor TM synthetic peptides on FRET signals of the 5-HT1A-FGFR1 receptor heterocomplexes. Values represent themaximal saturable normalized FRET values.Means SEM; n 4, 6
replicates.Statisticalanalysiswasperformedbyone-wayANOVAfollowedbyTukey’sMultipleComparisonposthoctest.TheFGFR1-GFP25HT1A-YFPandFGFR1-GFP25HT1A-YFPwithTMpeptideIIgroups
aswell as thechimeragroup(GFP2-YFP)are significantlydifferent fromtheFGFR1-GFP25HT1A-YFPwithTMpeptideVgroupalone (p0.001and***p0.001, respectively). Theconcentrationof
the synthetic TMpeptides used is 0.4M in all experiments.
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In line with these results, extensive colocalization of FGFR1
and 5-HT1A immunoreactivities was observed in the nerve cells
of the dorsal raphe and the median raphe (Fig. 1D).
Raphe RN33B cells: In situ PLA
The existence of FGFR1–5-HT1A receptor complexes was also
demonstrated with PLA in raphe RN33B cells. Themean number
of PLA red clusters per cell was found to be significantly increased
by FGF-2 or 8-OH-DPAT treatment alone, and this increase was
significantly enhanced upon combined treatment (Fig. 1E,e1).
HEK293T cells: FRET technique
A saturation FRET curvewas obtained inHEK293T cells coexpress-
ing a constant amountof theFGFR1-GFP2plasmidwhile increasing
the amount of the 5-HT1A-YFP plasmid but not with the 5-HT2A-
YFP plasmid. Cotransfection of FGFR1 and 5-HT2A led only to a
linear regression and thus these receptors failed to specifically inter-
act (Fig. 1F). Treatment of 5HT1A-FGFR1-cotransfected cells with
FGF-2 and 8-OH-DPAT significantly reduced the FRET50 values
and increased the FRETmax signal (Fig. 1F). Thus, the combined
treatment substantially increases the recruitmentof the receptorhet-
erocomplex and increases the affinity of the interaction between the
two protomers. In preliminary FRET experiments we observed that
the most important TM interface interaction between the FGFR1–
5-HT1A receptor corresponds to the TM-V and potentially also
TM-VII. Incubations with TM-IV and TM-VI failed to block the
FRET signal (see Notes). FRET competition experiments with syn-
thetic peptides of TM-II and TM-V of the 5-HT1A receptor were
performed (Fig. 1f1). TM-V incubation resulted in a significant loss
of the 5HT1A capacity to interact with FGFR1, where TM-II was
totally ineffective.
FGFR1 transactivation, ERK1/2 phosphorylation, and
differentiation of RN33B cells
The 5-HT1A agonist modulation of the FGFR1 agonist-response in
RN33B cells is displayed in Figure 2A. Both the 5-HT1AandFGFR1
agonists produced a rise of FGFR1 phosphorylation with combined
treatment resulting in a synergistic action. The 8-OH-DPAT en-
hancement of FGFR1 transactivation is counteracted by both
5-HT1A (S-WAY-10013) and FGFR1 (PD173074) antagonists.
The consequences of the 5-HT1A-induced increase in pFGFR1
on its signaling were studied by analysis of single and combined
FGF-2 and 8-OH-DPAT treatment on ERK1/2 phosphorylation
(Fig. 2B). The synergistic increase of pERK1/2 by combined FGF-2
and 5-HT1A agonist treatment was blocked by FGFR1 inhibitors
and by the 5-HT1A antagonist and in siRNAfgfr1- or siRNA5ht1a-
transfected cells. Nonsilencing siRNA control did not block this in-
crease in the pERK1/2 (Fig. 2B). Proper controls for the silencing
effect of each siRNA were done on induction of CREB and SRE
promoters (see Notes). Similar results on pERK1/2 by combined
FGF-2and5-HT1Aagonist treatmentwereobtained incells thathad
been differentiated before agonist treatment by means of an eleva-
tion of temperature to 39°C for 48 h (see Notes).
The time course experiments of ERK1/2 phosphorylation are
shown in Figure 2C. Combined treatment with the 5-HT1A and
FGFR1 agonists produced a synergistic increase of ERK1/2 phos-
phorylation starting already after 5 min and was still maintained
after 120 min.
It is of substantial interest that the receptor interface of the
FGFR1–5-HT1A receptor complex appeared to be crucial for this
synergism since it was counteracted by incubation with TM-V of
the 5-HT1A receptor but not with TM-II (Fig. 2A,C). Thus, the
5-HT1A agonist-induced synergistic activation of both FGFR1
transactivation and ERK1/2 phosphorylation appears to be de-
pendent on the receptor interface of the FGFR1–5-HT1A recep-
tor heterocomplex.
To obtain amorphological correlate to the synergistic increase
of pERK1/2 seen with FGF-2 and the 5-HT1A agonist cotreat-
ment, effects of this combined treatment have been studied on
RN33B cell differentiation (number and length of neurites, and
degree of 5-HT immunoreactivity). In Figure 2D it is demon-
strated that this combined treatment produced a highly signifi-
cant increase in the number of extensions per 1000 RN33B cells
after a 24–48 h incubation. The neuritic extensions were much
longer and the cell somata more elongated (Fig. 2D). This in-
crease was blocked not only by FGFR1 inhibitors and by the
5-HT1A antagonist (data not shown) but also by TM-V, while
TM-II was ineffective.
Potential effects of 5HT1A-FGFR1 receptor heterocomplex
on the serotonergic properties of RN33B cells showed that in the
absence of agonist treatment, very few RN33B cells were 5-HT
positive (Fig. 2E). Semiquantitative image analysis showed that
FGF-2 incubation caused an increase in the number of 5-HT-
immunoreactive RN33B cells with high fluorescence intensity.
Robust increases in 5-HT immunoreactivity were only seen with
combined treatment. RN33B cells cultured in the presence of
8-OH-DPAT alone did not increase 5-HT immunoreactivity
above control levels. In addition, no significant differences in the
number of high-5-HT IR-expressing cells were detected from
that seen with FGF-2 alone when cells were incubated in the
presence of synthetic peptide TM-V.
FGFR1 transactivation and ERK1/2 phosphorylation in the
caudal midline area of the midbrain after in vivo treatment
with FGF-2 and/or 8-OH-DPAT given
intracerebroventricularly
In vivo results have been obtained by exploring the effects of
intracerebroventricular treatment with 8-OH-DPAT (200 nmol)
and/or FGF-2 (50 ng) on pFGFR1 and pERK1/2 levels in the rat
caudal midline area of the midbrain containing the dorsal and
median raphe nuclei (Fig. 3A,B). Upon combined intracerebro-
ventricular treatment with 8-OH-DPAT and FGF-2, a synergistic
and significant increase of phosphorylation of FGFR1 and
ERK1/2 was observed at 6, 12, and 24 h in the caudalmidline area
of the midbrain. As seen in Figure 3, a1 and b1, prior intracere-
broventricular treatment (1 h) with TM-V but not with TM-II
markedly counteracted the synergistic increase of the FGFR1 and
ERK1/2 phosphorylation found after combined treatment with
the FGF-2 and 8-OH-DPAT as seen in the 6–24 h time interval
studied.
Discussion
We show for the first time the existence of FGFR1–5-HT1A re-
ceptor heterocomplexes in 5-HT nerve cells of the dorsal and
median raphe nuclei of the midbrain by means of the PLA tech-
nique as has previously been postulated (Fuxe et al., 2007). These
5-HT neurons are known from previous work to express FGFR1
and to contain high amounts of 5-HT1A immunoreactivity and a
high density of 5-HT1A binding sites (Pazos and Palacios, 1985;
Albert et al., 1996; Artigas et al., 1996; Belluardo et al., 1997).The
PLA-positive clusters have a location in the cytoplasm and are
also associatedwith the plasmamembrane. Theywere in addition
demonstrated with the PLA technique in stable cell lines from the
medullary raphe neurons, all showing observable 5-HT IR in
their cytoplasm in agreement with previous work (Czesak et al.,
2007). The specificity of the in situ PLA was indicated from the
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Figure 2. FGFR1–5-HT1A receptor–receptor interactions involving FGFR1 transactivation, ERK1/2 phosphorylation, and structural plasticity in RN33B cells. A, B, Synergistic activation of the FGFR1 and
ERK1/2 phosphorylation is induced by coactivation of 5-HT1A and FGFR1 in raphe RN33B cells. A, Left, An in cell Western assay was used to measure 8-OH-DPAT concentration response effects of FGFR1
phosphorylation in RN33B cells coexpressing 5-HT1A and FGFR1 receptors. Similar experiments were performed without stimulation (vehicle) and in the presence of the selective 5-HT1A antagonist S-WAY
10013 (1M). Thedata represent themean SEM;n3 in quadruplicates. Statistical analysiswas performedby one-wayANOVA followedby Tukey’sMultiple Comparisonpost hoc test. 8-OH-DPAT50nM,
100 nM, and 250 nM groups are significantly different comparedwith vehicle (**p 0.01, ***p 0.001, ***p 0.001, respectively); combined 8-OH-DPAT S-WAY 10013 group is significantly different
comparedwith8-OH-DPAT50nM, 100nM, and250nMgroups (p0.05, p0.001, p0.001, respectively). Right, The synergistic increase of FGFR1phosphorylation is blockedby the5-HT1A
TMpeptideV.Thefollowingconcentrationswereused:8-OH-DPAT(100nM),FGF-2(5ng/ml),PD173074(60nM),S-WAY10013(1M),andeachTMpeptide(0.4M).Combinedtreatmentgroupissignificantly
different from 8-OH-DPAT and FGF-2 alone ( ###p 0.001 and p 0.01, respectively); the combined treatment groups with TM peptide V, 5-HT1A antagonist, and FGFR1 inhibitor, respectively, are
significantlydifferent fromthecombinedtreatmentgroupalone(***p0.001).Statisticalanalysiswasperformedbyone-wayANOVAfollowedbyTukey’sMultipleComparisonposthoc test.B, Thesynergistic
increase of the ERK1/2 phosphorylation is blocked by the 5-HT1A TM peptide V, the siRNAfgfr1 and siRNA5ht1a, but not by TM-II and the nonsilencing siRNA Alexa Fluor 488 (siRNAcont). The following
concentrations were used: 8-OH-DPAT (100 nM), FGF-2 (5 ng/ml), PD173074 (60 nM), S-WAY10013 (1M), and each TM peptide (0.4M). Combined treatment group is significantly different from the
8-OH-DPAT and FGF-2 alone groups (p 0.001); the combined treatment groupswith TM peptide V, 5-HT1A antagonist, and FGFR1 inhibitor are significantly different from the combined treatment
groupalone (***p0.001); aswell, the siRNAfgfr1andsiRNA5ht1agroupsmarkedlyblock the synergistic effectof the combined treatmentgroup (***p0.001).DataaremeanSEM,n5.C, Timecourse
of ERK1/2 phosphorylation was significantly different in the range of 5–120min between the combined treatment group and FGF-2 alone and 8-OH-DPAT alone (based on the area values under the curve,
***p 0.001) by one-way ANOVA followed by Tukey’sMultiple Comparison post hoc test.With this analysis a significant difference between FGF-2 alone and 8-OH-DPAT alonewas observed at 10–15min
(*p0.05).DataaremeansSEM,n6.D, 5-HT1AagonistmarkedlyenhancedFGF-2-mediatedRN33Bcell differentiation (neuritedensity).UndifferentiatedRN33Bcellswere treatedwithout (vehicle)or
with FGF-2 (50ng/ml) and/or 8-OH-DPAT (100nM), in thepresenceof TM-II andTM-V (0.4M) as indicated. Each24h, themediumwas replacedand fresh ligandswere added.After a total incubation timeof
3d,thecellswerefixedandphotographed.Extensionswereanalyzedunder lightmicroscopy.Averagenumberofextensionsper1000cellsandmeanlengthper100cellsaregiven.Scalebar,25mforallpanels.
d1,Thequantification isseen;dataarepresentedasmeanSEM(n4).Thecombinedgroupissignificantlydifferent from8-OH-DPATandFGF-2alone(p0.001); thegrouptreatedwithTMpeptide
V (0.4M) is highly significantly reducedversus the combined treatedgroup (**p0.01); FGF-2 is significantlydifferent from8-OH-DPATalone ( #p0.05).d2, Extension lengths/100 cells arepresented for
thevarioustreatmentgroupsasascatterplot.Thequantification includesthecalculationofmeanSEM,n3.Thecombinedgroupissignificantlydifferent from8-OH-DPATandFGF-2alone(***p0.001);
combinedgroupaswell as treatedTMpeptide IIgroup ishighly significantly increasedversus thecontrolandtreatedwithTMpeptideVgroup(p0.001). Statistical analysiswasperformedbyone-way
ANOVA followedby Tukey’sMultiple Comparisonpost hoc test. TheP value 0.05 and lowerwas considered significant.E, Effects of TMpeptide incubation on5-HT immunoreactivity in RN33B cell cultures after
coactivationwith 8-OH-DPAT and FGF-2,which produces amarked rise of 5-HT immunoreactivity [5-HT immunoreactivity (red color)was used as amarker for 5-HT synthesis and storage andNeuN immuno-
reactivity (green color) as amarker for neuronal nuclei]. RN33Bbrain-derived immortalized cellswere treated for 48hwithout (Control) orwith FGF-2 (50ng/ml) and8-OH-DPAT (100nM). Treatmentwith TM
peptides (0.4M) involvedTM-IIandTM-Vas indicated.5-HT immunoreactivitywasdeterminedafter immunofluorescent labelingwith5-HT/NeuNbymeasuring fieldareaof5-HT immunoreactivity insample
fieldsofa constant sizedividedby thenumberofNeuNnuclei. Representative imagesof5-HT/NeuN-stainedRN33Bcellsunderdifferent conditionsarepresented. Scalebar, 20m.Thequantification is seen in
e1,where thedataarepresentedasmeanSEM,n4. The combinedgroup is significantlydifferent from8-OH-DPATandFGF-2alonegroups (p0.001); themean5-HT immunoreactivity valueof
the group treatedwith TMpeptide V is highly significantly reduced versus the combined treated group (***p 0.001). Also the FGF-2-treated alone group is significantly different from the 8-OH-DPAT alone
group ( ##p 0.01). The following concentrationswere used: 8-OH-DPAT, 100 nM; FGF-2, 50 ng/ml; and each TMpeptide, 0.4M. Statistical analysis was performed by one-way ANOVA followed by Tukey’s
Multiple Comparisonpost hoc test. TheP value 0.05 and lowerwas considered significant.
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absence of the PLA cluster in HEK293T cells singly transfected
with FGFR1 and 5-HT1A. These results are supported by the
findings of coimmunoprecipitation of FGFR1 and 5-HT1A in the
caudal midline region of the midbrain, containing the dorsalis
and median raphe nuclei. Also a colocation of the FGFR1 and
5-HT1A immunoreactivities was demonstrated in themajority of
the 5-HT nerve cells within the dorsal and median raphe.
With the FRET technique the FGFR1–5-HT1A receptor het-
erocomplexes were also demonstrated in HEK293T cells tran-
siently cotransfected with FGFR1-GFP2 and 5-HT1A-YFP. The
FRET results also indicated that combined treatment with FGF-2
and 8-OH-DPATmay recruit an increased number of FGFR1–5-
HT1A receptor heterocomplexes in view of the increased Bmax
values observed with this combined treatment. In line with this
interpretation the number of PLA-positive clusters per nerve cell
markedly increased upon this cotreatment. This increase was
blocked by incubationwith TM-V peptide but not TM-II peptide
of the 5-HT1A receptor, indicating that TM-V is part of the re-
ceptor interface.
These results together opened up the possibility that the
5-HT1A autoreceptors may in addition participate in the neuro-
trophism of the central 5-HT nerve cells via the formation of
FGFR1–5-HT1A receptor heterocomplexes which may be dy-
namically regulated by combined agonist treatment.
It could in fact be demonstrated in the stable cell lines of the
medullary raphe neurons that FGF-2 and 5-HT1A agonist co-
treatment produced a marked enhancement of the number of
processes formed by each medullary raphe cell and of the
amounts of 5-HT immunoreactivity per cell. These plastic
changes were specific since they were blocked by FGFR1 inhibi-
tors and 5-HT1A antagonists and by siRNAs for FGFR1 and for
5-HT1A. The dependency of the receptor heterocomplex was
indicated by the ability of the TM-V but not TM-II peptide to
block these plasticity events. Thus, the results indicate that the
FGFR1–5-HT1A receptor heterocomplexes may increase the
plasticity of the medullary raphe 5-HT nerve cells. In agreement,
this cotreatment using the same cell model led to a marked syn-
ergistic increase in the FGFR1 and ERK1/2 phosphorylation lev-
els vs single treatment with the agonists. Like the structural
plasticity events these signaling events were specific since they
were blocked by FGFR1 inhibitors and 5-HT1A antagonists and
by siRNAs for FGFR1 and for 5-HT1A. The dependency of the
receptor heterocomplex was again indicated by the ability of the
TM-V but not TM-II peptide of the 5-HT1A receptor to block
these plasticity events. This increase in ERK signaling, likely in-
volved inmediating the increase in structural plasticity observed,
may be produced by the observed 5-HT1A agonist-induced
transactivation of the FGFR1 as seen from its increased phos-
Figure 3. A, B, FGFR1 transactivation and ERK1/2 phosphorylation after intracerebroventricular treatment with FGF-2 and 8-OH-DPAT in the caudal midline area of the midbrain. Synergistic
activation of ERK1/2 phosphorylation and FGFR1 phosphorylationwas observed in the caudal midline area of the ratmidbrain containing the dorsal andmedian raphe nuclei after intracerebroven-
tricular coinjection of FGF-2 (50 ng) and/or 8-OH-DPAT (200 nmol). Data aremean SEM. Three rats per group (total of 12 groups). The blots depicted are from two different animals (out of a total
of three rats per group). Combined treated group (8-OH-DPAT FGF-2) and the TM peptide II-treated group (TM-II, 0.4M 8-OH-DPAT FGF-2) are significantly different from FGF-2 and
8-OH-DPAT alone group and the TMpeptide V-treated group (TM-V, 0.4M 8-OH-DPAT FGF-2) at the time points studied (FGFR1 transactivation, *p 0.05; ERK1/2 phosphorylation, **p
0.01); activation of ERK1/2 at 6 h in the FGF-2 alone group and the TM peptide V-treated groupwas significantly different from that in the 8-OH-DPAT alone group (p 0.05). Statistical analysis
was performed by two-way ANOVA followed by Bonferroni’s post hoc test. The P value 0.05 and lower was considered significant.
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phorylation levels. The molecular mechanism may involve an
enhancing allosteric receptor–receptor interaction in the recep-
tor heterocomplex (Fuxe et al., 2007).
The studies using intracerebroventricular injections of FGF-2
and/or the 5-HT1A agonist 8-OH-DPAT in rats gave in vivo ev-
idence that the cotreatment with these agonists can synergisti-
cally increase ERK1/2 and FGFR1 phosphorylation levels in the
caudal midline region containing the dorsal and median raphe
nuclei rich in 5-HT nerve cell bodies (Dahlstroem and Fuxe,
1964). Thus, both in vitro and in vivo findings support the view
that the signaling of the FGFR1–5-HT1A receptor heterocom-
plexes in the dorsal andmedian raphe 5-HT nerve cells may have
a role in enhancing neuroplasticity in these neurons. It is of sub-
stantial interest that intracerebroventricular TM-V of the
5-HT1A receptor, which belongs to the receptor interface, can
markedly counteract the synergistic increase in FGFR1 and
ERK1/2 phosphorylation after combined intracerebroventricular
treatmentwith FGF-2 and 8-OH-DPAT. These results in fact give
evidence that the FGFR1–5-HT1A receptor heterocomplexes are
involved in mediating these actions in the brain. This strongly
supported by the observation that intracerebroventricular TM-
II, which does not belong to the receptor interface, in the same
dose failed to counteract these effects.
It should be noticed that BDNF, known to have antidepressant-
like effects (Siuciak et al., 1997), in primary raphe cultures produces
increases in neuritic lengths of 5-HT nerve cells via TrkB receptors,
which are higher in the absence of 5-HT1A receptors (Rumajogee et
al., 2004). These results indicate that there exist in embryonic devel-
opment indirect or direct TrkB-5-HT1A receptor interactions in
5-HT nerve cells which are antagonistic in nature. Should TrkB-5-
HT1A receptor heterocomplexes exist in the raphe 5-HTnerve cells,
the receptor–receptor interactions within them are therefore likely
antagonistic in contrast to the synergistic receptor–receptor interac-
tions found in the current study in the discovered FGFR1–5-HT1A
receptorheterocomplexes in themidbrainraphe5-HTnervecells. In
addition, theenhancementof theneuritic lengthsof5-HTnervecells
observed in the 5-HT1A-null mutant mice may be possible also
through a compensatory mechanism involving the formation of
FGFR1–5-HT1B receptor heterocomplexes.
Together, the results show that the 5-HT1A autoreceptors by
being part of a FGFR1–5-HT1A receptor heterocomplex in the
midbrain raphe 5-HTnerve cells appears to have a functional role
in the central 5-HT neuron systems in addition to playing a key
role in reducing the activity of these neurons as an autoreceptor
(Albert et al., 1996; Artigas et al., 1996). Thus, by transactivation
of FGFR1 in this receptor heterocomplex and increasing its
ERK1/2 signaling, itmay improve the neuroplasticity of the 5-HT
nerve cells, whichmay contribute to antidepressant-like effects. It
may be speculated that certain types of depressionmay develop as
a result of a disruption of the FGFR1–5-HT1A receptor hetero-
complex reducing the neuroplasticity and trophism of the central
5-HT neurons and leading to dysregulation of the 5-HT1A auto-
receptor with abnormal reductions of the firing rate in these neu-
rons. Future work will show whether this speculation has any
value in understanding mechanisms of major depression.
Notes
Supplemental material for this article is available at http://www.neuro.
ki.se/fuxe/borroto_escuela.html. Control experiments are presented
demonstrating disruptive actions by distinct transmembrane peptides of
the 5-HT1A-FGFR1 heterocomplex and the synergistic increase in
ERK1/2 phosphorylation after coactivation with 8-OH-DPAT and
FGF-2 in differentiated cells. The specificity of the siRNA-5ht1a and
siRNA-fgfr1 is demonstrated in CRE and SRE-luciferase reporter gene
assays including a pharmacological analysis. Coimmunoprecipitation of
FGFR1 and 5-HT1A is shown in the midbrain raphe tissue containing
nucleus raphe dorsalis and medianus. This material has not been peer
reviewed.
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